AMS:GLPG - Euronext Amsterdam - BE0003818359 - Common Stock - Currency: EUR
AMS:GLPG (3/7/2025, 7:00:00 PM)
24.5
-0.12 (-0.49%)
The current stock price of GLPG.AS is 24.5 EUR. In the past month the price increased by 10.96%. In the past year, price decreased by -22.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 646 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 683
Company Website: https://www.glpg.com/
Investor Relations: https://www.glpg.com/investor-center
Phone: 3215342900
The current stock price of GLPG.AS is 24.5 EUR. The price decreased by -0.49% in the last trading session.
The exchange symbol of GALAPAGOS NV is GLPG and it is listed on the Euronext Amsterdam exchange.
GLPG.AS stock is listed on the Euronext Amsterdam exchange.
20 analysts have analysed GLPG.AS and the average price target is 30.84 EUR. This implies a price increase of 25.87% is expected in the next year compared to the current price of 24.5. Check the GALAPAGOS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GALAPAGOS NV (GLPG.AS) has a market capitalization of 1.61B EUR. This makes GLPG.AS a Small Cap stock.
GALAPAGOS NV (GLPG.AS) currently has 683 employees.
GALAPAGOS NV (GLPG.AS) has a support level at 22.22 and a resistance level at 24.52. Check the full technical report for a detailed analysis of GLPG.AS support and resistance levels.
The Revenue of GALAPAGOS NV (GLPG.AS) is expected to decline by -6.96% in the next year. Check the estimates tab for more information on the GLPG.AS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLPG.AS does not pay a dividend.
GALAPAGOS NV (GLPG.AS) will report earnings on 2025-04-23.
The PE ratio for GALAPAGOS NV (GLPG.AS) is 13.24. This is based on the reported non-GAAP earnings per share of 1.85 and the current share price of 24.5 EUR. Check the full fundamental report for a full analysis of the valuation metrics for GLPG.AS.
ChartMill assigns a technical rating of 2 / 10 to GLPG.AS. When comparing the yearly performance of all stocks, GLPG.AS is a bad performer in the overall market: 90.7% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to GLPG.AS. Both the profitability and the financial health of GLPG.AS get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of 1.85. The EPS decreased by -54.06% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 23.04% | ||
ROA | 2.97% | ||
ROE | 4.24% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 50% to GLPG.AS. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 58.04% and a revenue growth -6.96% for GLPG.AS